KOS 2187
Alternative Names: KOS-2187; PF-04548043; PF-4548043Latest Information Update: 14 May 2009
At a glance
- Originator Kosan Biosciences
- Developer Pfizer
- Class Gastrokinetics
- Mechanism of Action Motilin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetic gastroparesis; Gastro-oesophageal reflux
Most Recent Events
- 17 Oct 2008 Updated MoA
- 27 Jun 2008 Kosan has been acquired by Bristol-Myers Squibb
- 06 Aug 2007 Phase-I clinical trials in Diabetic gastroparesis in USA (PO)